Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity

Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the Enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, Enzyme thermostabilization, and lysosomal translocation of GC.